investors.tokaipharma.com
Overview - Investors & Media - Tokai Pharmaceuticals
Tokai Pharmaceuticals is focused on developing and delivering innovative therapies that provide hope and healing for patients living with cancer. Tokai also has an ongoing program to identify and develop novel compounds designed to disrupt androgen receptor signaling through enhanced androgen receptor degradation. Tokai Pharmaceuticals Reports Second Quarter 2015 Results. ARMOR3-SV Represents the First Precision Medicine-Based Pivotal Clinical Trial in Prostate Cancer; Topline Data Expected by the End of...
investors.tokaipharmaceuticals.com
Tokai Nasdaq | Investors & Media | Overview
160; 0.02. Data provided by Nasdaq. Minimum 15 minutes delayed. Tokai Pharmaceuticals and Otic Pharma Enter into Share Purchase Agreement. Tokai Pharmaceuticals Announces Review of Strategic Alternatives. Tokai Pharmaceuticals Announces Reduction in Force. BOSTON- (BUSINESS WIRE)- Jul. 29, 2016- Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announ...Tokai...
investors.tornos.com
Welcome to the investors' area | Tornos Investors
Control and warding-off mechanisms. Information and disclosure policy. Participation rights of shareholders. Control and warding-off mechanisms. Information and disclosure policy. Participation rights of shareholders. Tornos Group is one of the global leaders for the development, production and distribution of Swiss-type automatic lathes and multi-spindle machines. The company’s history dates back to 1880 and marked the beginning of Swiss-type lathe technology. Subscribe to Tornos news.
investors.totalproduce.com
Investors – Total Produce plc
Irish Stock Exchange (Currency EUR). London Stock Exchange (Currency GBP). Total Produce plc raises 2016. VIEW ALL INVESTOR NEWS. Latest Results and Presentations. 2016 Interim Results Presentation. VIEW ALL RESULTS AND PRESENTATIONS. A Global Business with Local Knowledge. Total Produce PLC 29. North Anne Street, Dublin 7. D07 PH36, Ireland. 353 (0) 1 887 2600.
investors.towerinternational.com
Tower International Inc - Investor Relations - Corporate Overview
Tower International, Inc. is one of the largest independent global suppliers of automotive metal structural components and assemblies. We serve virtually every major automotive vehicle manufacturer, providing a broad range of metal structures from stampings to complex body and frame assemblies. Tower's global reach enables us to serve customers close to their assembly plants around the world. With corporate headquarters in Livonia, Michigan, U.S., our 8,700 colleagues support our c. 160; 0.51. Replicatio...
investors.trademe.co.nz
Investor Relations – Trade Me Group Ltd
Skip to main content. Trade Me's acquisition of Motorcentral declined by Commerce Commission. 09 March, 2018. In July 2017, Trade Me advised it had entered into a conditional agreement to purchase Limelight Software Limited, trading as Motorcentral (motorcentral.co.nz), a cloud-based dealer management pla. Continue. TME Interim Result: Record revenue underpinned by Classifieds strength. 28 February, 2018. Webcast info: Trade Me FY18 interim results. 14 February, 2018. Data as at 3/30/2018 5:36:30 PM.
investors.trendlines.com
Investors – Trendlines
Skip to main content. Trendlines invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies. We took two companies public and exited six companies. Director, Investor Relations and Corporate Communications. Romil Singh / Reyna Mei. Financial PR Pte Ltd. December 2016 Monthly Update. PrimePartners Corporate Finance Holdings Invests in Trendlines Medical. Financial Reports and Presentations. Investor Presentation January 2017. Q3 2016 Financial Results (Unaudited).
investors.trevena.com
Investor Relations - Trevena
What is a Biased Ligand? Trevena's ABLE Platform. History of Biased Ligands. Annual Reports and Proxies. Annual Reports and Proxies. We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Trevenas financial performance into perspective. Stock Quote (NASDAQ: TRVN). 4:00 PM ET on Jan 12, 2017. Delayed at least 20 minutes. Upcoming events are not available at this time. Sign up for email alerts.
investors.tribunemedia.com
Tribune Media Investor Relations - Investor Relations
Work/Life at Tribune Media. Work/Life at Tribune Media. TM (demo) About Tribune Media. Page,page-id-15747,page-parent,page-template,page-template-full width-php,ajax fade,page not loaded, ,wpb-js-composer js-comp-ver-4.2.3,vc responsive. Aug 13, 2015. Tribune Media Company Reports Second Quarter 2015 Results. Aug 6, 2015. Tribune Media Company Announces Resignation of Chief Financial Officer Steven Berns. Jul 31, 2015. Tribune Media Company Declares Quarterly Cash Dividend. No events to display.
investors.trivascular.com
Investors - TriVascular Technologies Inc.
Annual Reports and Proxies. Aug 4, 2015. TriVascular Technologies, Inc. Reports Second Quarter Financial Results. Aug 4, 2015. TriVascular Technologies, Inc. Receives FDA Approval of the Ovation iX(TM) Abdominal Stent Graft System. View all press releases ». Aug 12, 2015 at 8:00 AM ET. Canaccord Genuity Growth Conference. Aug 4, 2015 at 1:30 PM PT. TRIV 2Q15 Earnings Conference Call. View all events and presentations ». Instructions for Use, Indications, Contraindications, and Caution Statement.
investors.tropicanacasinos.com
Profile
Belle of Baton Rouge. 8212; Main Menu —. Belle of Baton Rouge. Tropicana Atlantic City Online Casino. Belle of Baton Rouge. Tropicana Atlantic City Online Casino. Tropicana Entertainment owns premier gaming resort properties throughout the United States. This page is where you'll find the latest news, SEC filings and financial information on the Las Vegas, Nevada-based company's casinos and gaming resorts across the United States. Telephone: 702.589.3827. Sep 06, 2017. Aug 10, 2017. Jul 06, 2017.
